Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA Ph: +1-203-852-6800, 800-243-6002 ...

Saudi Society of Dermatology and Sanofi Sign MoU to Advance Dermatological Care in Saudi Arabia ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Shares of Corvus Pharmaceuticals, Inc. (CRVS) traded 30% higher on Friday afternoon after Oppenheimer raised its price target ...

Researchers have found in a new study published in Laryngoscope that effective treatment of upper airway atopic diseases ...

Sanofi to showcases leadership and breadth of scientific innovation in chronic inflammatory respiratory conditions at ATS conference: Paris Saturday, May 3, 2025, 16:00 Hrs [IST] ...

Pulmonologists alarmed by climate-linked asthma surge, find hope in novel medications: Nandita Vijayasimha, Bengaluru Tuesday, May 6, 2025, 08:00 Hrs [IST] Pulmonologists associat ...

Patients who are immunocompromised still can receive a variety of vaccinations based on their specific needs, Cassandra ...